Zealand Pharma's petrelintide shows weight loss in Type 2 diabetes trial
Tweet Send to a Friend
Zealand Pharma A/S (Nasdaq: ZEAL) reported positive topline results from its Phase 2 ZUPREME-2 trial, in which the amylin analog ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




